Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
International Journal of Molecular Sciences · 31.07.2023 · 24 (15) · 12232
DOI: 10.3390/ijms241512232 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.07.2023. Verfasst von Florian Plaza Oñate und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, France. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Liver Neoplasms, Metabolic Diseases. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, French National Research Agency, MetaGenoPolis.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observe that compared to healthy controls, Adlercreutzia equolifaciens is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that A. equolifaciens possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of A. equolifaciens and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy for liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, France.
- NovoBiome, 33360 Latresne, France.
- Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, France.
- Enterome, 75011 Paris, France.
- Université d'Angers, SFR ICAT4208, Laboratoire HIFIH & Centre Hospitalier d'Angers, 49100 Angers, France.
- Sorbonne-Université, Hôpital Pitié-Salpêtrière, INSERM UMRS 1138, Centre de Recherche des Cordeliers, 75006 Paris, France.
ORCID-Profile: Florian Plaza Oñate, Sebastian D Burz, Nicolas Lapaque, Joël Doré, Philippe Gérard, Hervé M Blottière
Förderung
- Agence Nationale de la Recherche
- French National Research Agency
- MetaGenoPolis
Zitieren
APA
Oñate, F. P., Chamignon, C., Burz, S. D., Lapaque, N., Monnoye, M., Philippe, C., Bredel, M., Chêne, L., Farin, W., Paillarse, J. M., Boursier, J., Ratziu, V., Mousset, P. Y., Doré, J., Gérard, P., & Blottière, H. M. (2023). Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. International Journal of Molecular Sciences, 24(15), 12232. https://doi.org/10.3390/ijms241512232
Vancouver
Oñate FP, Chamignon C, Burz SD, Lapaque N, Monnoye M, Philippe C, et al. Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. International Journal of Molecular Sciences. 2023;24(15):12232. doi:10.3390/ijms241512232
BibTeX
@article{Oate2023,
author = {Oñate, Florian Plaza and Chamignon, Célia and Burz, Sebastian D and Lapaque, Nicolas and Monnoye, Magali and Philippe, Catherine and Bredel, Maxime and Chêne, Laurent and Farin, William and Paillarse, Jean-Michel and Boursier, Jérome and Ratziu, Vlad and Mousset, Pierre-Yves and Doré, Joël and Gérard, Philippe and Blottière, Hervé M},
title = {Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {15},
pages = {12232},
doi = {10.3390/ijms241512232}
}
EUVIMED